EBC-46

Mechanism of Action

Endothelial Cell Permeability and EBC-46: How Tigilanol Tiglate Disrupts Tumour Vascular Integrity

Examining the published research on how EBC-46 increases endothelial cell permeability, contributing to rapid vascular disruption in tumour microenvironments.

Regulatory

FDA Enforcement Discretion and Botanical Supplements: How EBC-46 Products Operate Within Established Precedent

How the FDA's consistent enforcement discretion framework applies to botanical supplements like EBC-46, and what established legal precedent means for the category.

Consumer Reports

Blushwood Berry Extract Shelf Life and Storage: Maintaining Supplement Potency Over Time

A practical guide to understanding how storage conditions affect blushwood berry extract supplement quality, and what shelf life means for EBC-46 products.

Human Trials

Wound Healing Timelines in EBC-46 Clinical Trials: What Published Data Shows About Post-Treatment Recovery

Reviewing the wound healing data from published tigilanol tiglate clinical trials and what recovery timelines tell us about the treatment mechanism.

Mechanism of Action

Mitochondrial Membrane Potential and EBC-46: How Tigilanol Tiglate May Influence Cellular Energy Pathways

Exploring the emerging research on how tigilanol tiglate's PKC-delta activation may affect mitochondrial membrane potential and downstream cellular energy dynamics.

Regulatory

Japan's PMDA and Tigilanol Tiglate: Regulatory Considerations for EBC-46 in Asia-Pacific Markets

An overview of how Japan's Pharmaceuticals and Medical Devices Agency evaluates novel botanical compounds and what this means for tigilanol tiglate.

Consumer Reports

Blushwood Berry Extract and Cognitive Focus: What Users Are Reporting About Mental Clarity

A look at emerging user reports about blushwood berry extract and cognitive focus, what the anecdotal patterns suggest, and how to evaluate claims responsibly.

Botany

Drying Methods and Tigilanol Tiglate Stability: How Post-Harvest Processing Affects Blushwood Seed Chemistry

How different drying and post-harvest processing techniques affect the chemical stability of tigilanol tiglate in Fontainea picrosperma seeds.

Human Trials

Patient-Reported Outcomes in Tigilanol Tiglate Trials: Quality of Life Beyond Tumour Shrinkage

How clinical researchers measure patient-reported outcomes in EBC-46 human trials and why quality of life data matters alongside tumour response metrics.

Mechanism of Action

Calcium-Dependent PKC Activation by EBC-46: Why the C1 Domain Matters

Examining how EBC-46 binds the C1 domain of protein kinase C isoforms and why calcium-dependent activation drives rapid tumour response in preclinical models.

Regulatory

EMA Scientific Advice and EBC-46: What Europe’s Regulatory Pathway Looks Like in 2026

An overview of how the European Medicines Agency scientific advice process applies to tigilanol tiglate and what it means for EBC-46 regulation in Europe.

consumer-reports

EBC-46 Supplement Evaluation 2026: Quality Markers, Safety, and Buyer Criteria

A structured buyer's guide to evaluating EBC-46 blushwood berry extract supplements — extraction ratios, third-party testing, format considerations, and safety red flags.